A better buy-in window may exist right now for Adicet Bio Inc. (ACET)

Adicet Bio Inc. (NASDAQ: ACET) stock jumped 6.51% on Friday to $8.84 against a previous-day closing price of $8.30. With 0.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.79 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.01 whereas the lowest price it dropped to was $8.36. The 52-week range on ACET shows that it touched its highest point at $21.87 and its lowest point at $7.42 during that stretch. It currently has a 1-year price target of $27.36. Beta for the stock currently stands at 2.28.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACET was up-trending over the past week, with a rise of 2.79%, but this was up by 5.49% over a month. Three-month performance dropped to -45.16% while six-month performance fell -48.66%. The stock lost -31.58% in the past year, while it has lost -1.12% so far this year. A look at the trailing 12-month EPS for ACET yields -1.46 with Next year EPS estimates of -2.00. For the next quarter, that number is -0.28. This implies an EPS growth rate of 60.00% for this year and -57.90% for next year.

Float and Shares Shorts:

At present, 41.64 million ACET shares are outstanding with a float of 38.35 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.77 million, which was 9.42% higher than short shares on Sep 14, 2022. In addition to Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA as the firm’s CEO, Pres & Director, Dr. Aya Jakobovits Ph.D. serves as its Founder & Independent Director.


Institutional Ownership:

Through their ownership of 98.16% of ACET’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 52.01% of ACET, in contrast to 25.86% held by mutual funds. Shares owned by individuals account for 22.58%. As the largest shareholder in ACET with 9.90% of the stake, RTW Investments LP holds 4,241,472 shares worth 4,241,472. A second-largest stockholder of ACET, Ecor1 Capital LLC, holds 3,560,700 shares, controlling over 8.31% of the firm’s shares. Cowen & Co. LLC is the third largest shareholder in ACET, holding 3,143,608 shares or 7.34% stake. With a 4.17% stake in ACET, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 1,786,453 shares are owned by the mutual fund manager. The Polar Capital Funds Plc – Biotech, which owns about 2.33% of ACET stock, is the second-largest Mutual Fund holder. It holds 1,000,000 shares valued at 8.94 million. Vanguard Total Stock Market Index holds 2.30% of the stake in ACET, owning 983,730 shares worth 8.79 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ACET since 11 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ACET analysts setting a high price target of $38.00 and a low target of $20.00, the average target price over the next 12 months is $27.36. Based on these targets, ACET could surge 329.86% to reach the target high and rise by 126.24% to reach the target low. Reaching the average price target will result in a growth of 209.5% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ACET will report FY 2022 earnings on 03/13/2024. Analysts have provided yearly estimates in a range of $0.91 being high and -$1.61 being low. For ACET, this leads to a yearly average estimate of -$1.27. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Adicet Bio Inc. surprised analysts by $0.00 when it reported -$0.53 EPS against a consensus estimate of -$0.53. The surprise factor in the prior quarter was -$0.10. Based on analyst estimates, the high estimate for the next quarter is $1.85 and the low estimate is -$0.62. The average estimate for the next quarter is thus -$0.28.

Summary of Insider Activity:

Insiders traded ACET stock several times over the past three months with 0 Buys and 6 Sells. In these transactions, 0 shares were bought while 102,235 shares were sold. The number of buy transactions has increased to 21 while that of sell transactions has risen to 47 over the past year. The total number of shares bought during that period was 408,412 while 471,598 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *